Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

88.06 +0.76 (+0.87%)
Official Closing Price Updated: 4:15 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
23 24 Next >
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... 
Via Benzinga
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
From Incyte and Syndax Pharmaceuticals
Via Business Wire
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Analyst Ratings For Incyte
 
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably. 
Via Chartmill
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
Via Benzinga
Topics Death
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi... 
Via Benzinga
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals. 
Via Chartmill
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s... 
Via Benzinga
Topics Economy Stocks
NASDAQ:INCY is not too expensive for the growth it is showing.
In the world of growth stocks, INCYTE CORP (NASDAQ:INCY) shines as a value proposition. 
Via Chartmill
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs. 
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Analyst Expectations For Incyte's Future
 
Via Benzinga
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Don't overlook INCYTE CORP (NASDAQ:INCY)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
Via InvestorPlace
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Stocks Chop As Wall Street Unpacks Powell Comments
Stocks are mixed at midday, as investors weigh remarks from Federal Reserve Chair Jerome Powell. 
Via Talk Markets
Topics Economy
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-time highs. 
Via Benzinga
Topics Stocks
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.